Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serenex has signed a clinical trial agreement or CTA with the Center for Cancer Research at the National Cancer Institute or NCI.
Subscribe to our email newsletter
Under this CTA, Guiseppe Giaccone, chief of the medical oncology branch at NCI and his colleague, Martin Gutierrez, will conduct a Phase I clinical trial with Serenex’s novel, oral, small molecule heat shock protein 90 (Hsp90) inhibitor, SNX-5422.
The clinical trial under this CTA is being funded by the NCI and conducted by the NCI intramural program. Serenex and CCR have jointly developed the clinical protocol and Serenex will provide the study drug. This study will evaluate the safety, tolerability and pharmacokinetics of SNX-5422 as well as certain novel efficacy biomarkers. Data from the trial will be submitted by Serenex under its current investigational new drug (IND) application.